Metastatic CRPC: Radium-223 and Abiraterone Do Not Mix

​ Results are in for the ERA 223 study, a phase 3 trial which examined adding radium-223 to abiraterone acetate and prednisone or prednisolone for patients with castration-resistant prostate cancer (CRPC) and bone metastasis. Previous studies have found that radium-223 prolongs overall survival and delays the onset of symptomatic skeletal events in patients with CRPC and bone metastasis, and the combination of abiraterone acetate plus prednisone or prednisolone has been shown to improv...
Continue reading

New Technology Effectively Predicts Prostate Cancer

The most accurate prostate progression prediction technology to date has been developed by researchers from the Icahn School of Medicine at Mount Sinai and the Keck School of Medicine at the University of Southern California. Existing methods of prostate cancer detection include multiparametric magnetic resonance imaging (MRI) and the Prostate Imaging Reporting and Data System Version 2, a five-point scoring scale that categorizes tumors found on the multiparametric MRI. Because they are subject...
Continue reading

New Targets Identified in BRCA-Mutated Cancers

Researchers at Brigham and Women's Hospital have identified two new genes that can impact BRCA2-deficient cancer through "synthetic lethality," which occurs when a combination of deficiencies in two or more genes leads to cell death that would not occur with one deficiency alone. Inactivation of BRCA1 or BRCA2, both important tumor suppressor genes named for their roles in breast cancer, increases a woman's risk of breast cancer by up to 80% and increases her risk of ovarian cancer by around 50%...
Continue reading

Germline Mutations’ Effects on Prostate Cancer

In the case of metastatic castration-resistant prostate cancer (mCRPC), mutations in germline DNA damage repair (gDDR) genes are found in a significant percentage of patients. However, the consequences of these mutations have until now been unknown. Scientists from the Prostate Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) have contributed to understanding the connection between mCRPC and germline mutations. In the researchers' study, published in the Journa...
Continue reading

New Biomarkers Offer Treatment Clues for Prostate Cancer

Most often, men diagnosed with prostate cancer have a low risk of progression (LRP). However, some men have intermediate or high risk of progression (IHRP). Physicians tend to overtreat or undertreat patients because they do not have a reliable way to accurately determine the risk of progression. A new study published in Mayo Clinic Proceedings has provided a potential solution to this dilemma. "We have discovered new molecular markers that can help guide men in their decisions about the course ...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.